Until December 1999 Stamp, 38, was finance director of the rapidly expanding specialist pharmaceuticals company, Shire Pharmaceuticals. In his time there the group grew from its flotation value of £106m in 1996 to £1.6bn in December 1999 following the completion of its merger with Roberts Pharmaceutical Corporation of the US.
Prior to joining Shire in 1994, Stamp was an assistant director, corporate finance at Lazard Brothers in London, having previously spent four years at KPMG Peat Marwick, where he trained.
Mark Dixon, Executive Chairman of Regus, said: ‘Stephen’s knowledge of the workings of the capital markets and his background in the City will be of great assistance to Regus as the company enters what will be an important and exciting year in its development.
‘In addition, his experience in the US, where he has been involved in building a substantial presence for Shire and in achieving a listing for Shire on NASDAQ, will also be of enormous value to Regus as our business expands in that market.’
Just one half of UK practices have implemented a pricing structure around auto enrolment implementation and advice - with many suffering increased costs
Deloitte's north-west Europe foray; BDO, Smith & Williamson investment paths; Shelley Stock Hutter; and Wilkins Kennedy discussed by editor Kevin Reed on our Friday Afternoon Live broadcast
Accountants should alter their perspective on auto-enrolment to maximise business opportunities, according to Eric Clapton.
Kevin Reed discusses whether new accountancy group Cogital can rival the Big Four...and its likely direction of travel